McCann Worldgroup has partnered with Cigna International Markets in their latest initiative, which is helping the world see stress differently.
Cigna introduced a plan to fully cover costs for expensive gene therapies, eliminating any out-of-pocket payments for customers.
Swiss drugmakers Novartis and Lonza separately deepened the companies’ push into so-called biosimilars, betting cheaper copies of name-brand drugs will make headway among cost-conscious insurers and governments.
Blue Cross Blue Shield of Massachusetts’ Alternative Quality Contract slowed the rate of medical spending growth by up to 12 percent while improving patient care over the course of eight years, according to a Harvard Medical School study published in the New England Journal of Medicine.
The Trump administration scrapped a proposal for lowering prescription medicine prices, backing down from a policy that would have required health insurers to pass on billions of dollars in rebates they receive from drugmakers to Medicare patients.
A federal appeals court panel expressed skepticism to Democratic calls to overturn the ruling of a Texas judge who found the landmark U.S. healthcare reform law unconstitutional.
The U.S. Supreme Court agreed to decide whether the federal government must pay insurers $12 billion under an Obamacare program aimed at encouraging them to cover previously uninsured people after the healthcare law was enacted in 2010.
U.S. President Donald Trump plans to issue an executive order asking health insurers and doctors to disclose new details about healthcare costs in an attempt to improve price transparency, the Wall Street Journal reported, citing people familiar with the matter.
UnitedHealth Group Inc. won anti-trust approval to buy DaVita Inc.’s primary and urgent care unit for $4.3 billion, the Federal Trade Commission said.
As concerns over the price of prescription medicine continue to make headlines as the country barrels toward another election, a new study from the Scripps Research bolsters an argument touted by the pharmaceutical industry over the rebate system.